News

AstraZeneca and Daiichi Sankyo's TROP2-directed antibody-drug conjugate (ADC) Datroway has been granted accelerated approval ...
MSD and Daiichi Sankyo have announced first subject dosing in the randomised IDeate-Prostate01 Phase III trial of ifinatamab deruxtecan (I-DXd) against docetaxel in individuals with metastatic ...
The FDA has blessed AstraZeneca and Daiichi Sankyo’s Datroway to treat patients with locally advanced or metastatic epidermal ...
Datroway is used to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment.
The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a ...
The US Food and Drug Administration (FDA) has approved AstraZeneca and Daiichi Sankyo's Datroway (Datopotamab deruxtecan) for ...
Like many other major pharmaceutical companies, AstraZeneca is facing a series of patent cliffs for key treatments in its ...
FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response ...
Daiichi Sankyo has more than 120 years of experience and scientific expertise. In 2019, they entered the oncology market in the UK, through a ground-breaking collaboration with AstraZeneca.
AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been granted accelerated approval by the US Food ...
DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and ...
Merck and Daiichi Sankyo have announced that the first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ...